Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.71 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.70 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133213 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL13863420 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973496 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL5527047 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22911186 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973426 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL24032894 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973497 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910831 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910800 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-12280226-B2 | Drug-coated balloon catheters for body lumens | UROTRONIC, INC. (US) | 2025-04-22 | — | — | US | claimed |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2025-03-13 | — | — | US | claimed |
| US-20250025673-A1 | METHOD FOR TREATMENT OF AIRWAY STRICTURE OR STENOSIS | AIRIVER MEDICAL, INC. | 2025-01-23 | — | — | US | claimed |
| CN-119303213-A | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240416013-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC, INC. | 2024-12-19 | — | — | US | claimed |
| US-12168108-B2 | Balloon catheters for body lumens | UROTRONIC, INC. (US) | 2024-12-17 | — | — | US | claimed |
| CN-118949148-A | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2024-11-15 | — | — | CN | claimed |
| US-12115286-B2 | Drug-coated balloon catheters for body lumens | UROTRONIC, INC. (US) | 2024-10-15 | — | — | US | claimed |
| US-20180104383-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-04-19 | — | — | US | claimed |
| EP-3285820-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | Urotronic, Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172343-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | UROTRONIC, INC. (US) | 2016-10-27 | — | — | WO | claimed |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | claimed |
| US-7445931-B2 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | BRESAGEN, INC. (US) | 2008-11-04 | — | — | US | claimed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1250119-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001054654-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| US-6022684-A | SCREENING FOR SUPPRESSORS OF INOSITOLPHOSPHORYLCERAMIDE SYNTHASE BY RECOMBINANTLY EXPRESSING GENE IN HOMOGENEOUS CULTURE, INCUBATING WITH EXCESS LABELED CERAMIDE AND LABELED PHOSPHATIDYLINOSITOL, AND IDENTIFYING INHIBITORY COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | CETP 948/4885THRB 266/4885MEN1 2428/4885 |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | CETP 237/4885THRB 3490/4885MEN1 2780/4885 |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | SGMS1, S1PR1, S1PR3 | CETP 543/4885THRB 3824/4885MEN1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.